Compare Regeneron Pharmaceuticals Inc (REGN) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Teradyne, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Teradyne, Inc. trades at $381.79 (market cap $55.82B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.46%). Which is the better fit depends on your goals.
| REGN | TER | |
|---|---|---|
Market Cap | $83.43B | $55.82B |
Sector | Health | Technology |
52-Week High | $852.03 | $483.84 |
52-Week Low | $555.51 | $112.24 |
Enterprise Value | $78.14B | $55.56B |
Dividend Yield | 0.46% | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Teradyne (TER) trades at $372.06, up 4.21% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $3.19B in 2025, and net income margin stands at 25.77%. Analyst sentiment is positive, with a consensus price target of $474.78 and no sell ratings among 31 analysts. Recent news highlights surging demand for UltraFLEXplus systems driven by AI and data center growth.
The outlook for TER is favorable, supported by robust AI-driven demand, earnings momentum, and institutional accumulation. Key risks include competitive pressures from KLA and Cohu, reliance on semiconductor cycles, and execution challenges in scaling operations. The stock offers upside potential but remains sensitive to tech sector volatility and macroeconomic conditions affecting capital expenditure trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
